Strata Critical Medical Inc(SRTA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.19 | Insider Own | 24.36% | Shs Outstand | 88.5M | Perf Week | 0.85% |
| Market Cap | 0.42B | Forward P/E | 1426.43 | EPS next Y | 103.6% | Insider Trans | -0.65% | Shs Float | 66.9M | Perf Month | -7.05% |
| Enterprise Value | 0.40B | PEG | - | EPS next Q | -0.01 | Inst Own | 60.81% | Short Float | 6.78% | Perf Quarter | -5.38% |
| Income | -0.02B | P/S | 1.64 | EPS this Y | 63.39% | Inst Trans | -2.63% | Short Ratio | 4.93 | Perf Half Y | -5.38% |
| Sales | 0.26B | P/B | 1.5 | EPS next 5Y | - | ROA | -7.84% | Short Interest | 4.54M | Perf YTD | -1.25% |
| Book/sh | 3.16 | P/C | 18.25 | EPS past 3/5Y | 20.73% 20.42% | ROE | -9.22% | 52W High | -26.92% ($6.50) | Perf Year | -5.94% |
| Cash/sh | 0.26 | P/FCF | - | Sales past 3/5Y | 10.5% - | ROIC | -5.82% | 52W Low | 20.25% ($3.95) | Perf 3Y | 125.12% |
| Dividend Est. | - | EV/EBITDA | 48.6 | EPS Y/Y TTM | 19.57% | Gross Margin | 16.67% | Volatility(W/M) | 3.24% 3.66% | Perf 5Y | -49.84% |
| Dividend TTM | - | EV/Sales | 1.57 | Sales Y/Y TTM | 0.64% | Oper. Margin | -3.04% | ATR (14) | 0.18 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.64 | EPS Q/Q | -165.22% | Profit Margin | -6.42% | RSI (14) | 47.43 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.64 | Sales Q/Q | 2.41% | SMA20 | 2.77% ($4.62) | Beta | 2.55 | Target Price | $9.56 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/11/3 | SMA50 | -7.5% ($5.14) | Rel Volume | 1.36 | Prev Close | $4.76 |
| Employees | 601 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -500% 7.24% | SMA200 | -6.93% ($5.1) | Avg Volume(3M) | 0.92M | Price | $4.75 |
| IPO | 2019/11/5 | Option/Short | Yes/Yes | Trades | 6832 | Volume | 1,246,403 | Change | -0.21% |
🫀 Strata Critical Medical (ticker SRTA) is a U.S. healthcare facility company whose core business centers on organ transplant logistics and clinical support services. The company previously operated in the air mobility sector before shifting its focus toward medical logistics, and is steadily expanding its footprint in non-discretionary demand areas such as organ transportation and cardiovascular surgical support.
Over the past 1 year, roughly in the middle
27% below its 1-year high.
Traded more than usual. That is 136% of its average volume.
Next earnings report: November 3
4 days to go.
SRTA has a sound balance sheet but weak earning power
Of every $100 in sales, $3.04 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +63.4% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $164. Peers typically go for $89. It is about in line with its own 1-year average.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -49.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 60.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #34 of 48 in the industry
Based on market cap of $420M.
STLN#32 Starling Oncology Inc $665M PER - 
GMRS#33 GMR Solutions Inc $617M PER - SRTA#34 Strata Critical Medical Inc $420M PER - 
AUNA#35 Auna SA $355M PER 87.9 
CYH#36 Community Health Systems Inc $340M PER 9.6 
FAQ
What kind of company is SRTA?
SRTA belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of SRTA?
The market cap of SRTA is approximately $420M, ranking 3,303 within its sector.
What is the 52-week high and low for SRTA?
SRTA has recorded a 52-week high of $6.50 and a low of $3.95.
